Point-of-Care Testing for Infectious Diseases: Past, Present, and Future
- PMID: 28539345
- PMCID: PMC5527409
- DOI: 10.1128/JCM.00476-17
Point-of-Care Testing for Infectious Diseases: Past, Present, and Future
Abstract
Point-of-care (POC) diagnostics provide rapid actionable information for patient care at the time and site of an encounter with the health care system. The usual platform has been the lateral flow immunoassay. Recently, emerging molecular diagnostics have met requirements for speed, low cost, and ease of use for POC applications. A major driver for POC development is the ability to diagnose infectious diseases at sites with a limited infrastructure. The potential use in both wealthy and resource-limited settings has fueled an intense effort to build on existing technologies and to generate new technologies for the diagnosis of a broad spectrum of infectious diseases.
Keywords: infectious disease; lateral flow immunoassay; molecular diagnostic; point-of-care; rapid tests.
Copyright © 2017 American Society for Microbiology.
Similar articles
-
Advances in addressing technical challenges of point-of-care diagnostics in resource-limited settings.Expert Rev Mol Diagn. 2016;16(4):449-59. doi: 10.1586/14737159.2016.1142877. Epub 2016 Feb 24. Expert Rev Mol Diagn. 2016. PMID: 26777725 Free PMC article. Review.
-
The impact of digital technologies on point-of-care diagnostics in resource-limited settings.Expert Rev Mol Diagn. 2018 Apr;18(4):385-397. doi: 10.1080/14737159.2018.1460205. Epub 2018 Apr 10. Expert Rev Mol Diagn. 2018. PMID: 29658382 Review.
-
Future potential of Rapid Acceleration of Diagnostics (RADx Tech) in molecular diagnostics.Expert Rev Mol Diagn. 2021 Mar;21(3):251-253. doi: 10.1080/14737159.2021.1898950. Epub 2021 Mar 9. Expert Rev Mol Diagn. 2021. PMID: 33653217 Free PMC article. No abstract available.
-
Emerging technologies in point-of-care molecular diagnostics for resource-limited settings.Expert Rev Mol Diagn. 2014 Jun;14(5):525-34. doi: 10.1586/14737159.2014.915748. Epub 2014 May 2. Expert Rev Mol Diagn. 2014. PMID: 24784765 Review.
-
Use of CLIA-waived point-of-care tests for infectious diseases in community pharmacies in the United States.Expert Rev Mol Diagn. 2016;16(2):253-64. doi: 10.1586/14737159.2015.1116388. Epub 2015 Nov 27. Expert Rev Mol Diagn. 2016. PMID: 26560318 Review.
Cited by
-
Affordable mobile microfluidic diagnostics: minimum requirements for smartphones and digital imaging for colorimetric and fluorometric anti-dengue and anti-SARS-CoV-2 antibody detection.Wellcome Open Res. 2021 Mar 11;6:57. doi: 10.12688/wellcomeopenres.16628.1. eCollection 2021. Wellcome Open Res. 2021. PMID: 36312459 Free PMC article.
-
An integrated biosensor system with mobile health and wastewater-based epidemiology (iBMW) for COVID-19 pandemic.Biosens Bioelectron. 2020 Dec 1;169:112617. doi: 10.1016/j.bios.2020.112617. Epub 2020 Sep 16. Biosens Bioelectron. 2020. PMID: 32998066 Free PMC article.
-
Development of a Lateral Flow Assay for the Detection of the Hepatitis C Virus Core Antigen.Pharmaceuticals (Basel). 2024 Aug 4;17(8):1022. doi: 10.3390/ph17081022. Pharmaceuticals (Basel). 2024. PMID: 39204127 Free PMC article.
-
Reduction in cycle time for a rapid polymerase chain reaction diagnostic test at the point of care.J Infect Prev. 2023 Jan;24(1):23-29. doi: 10.1177/17571774221148072. Epub 2023 Jan 2. J Infect Prev. 2023. PMID: 36636172 Free PMC article.
-
Production and characterization of monoclonal antibodies for the detection of the hepatitis C core antigen.Front Mol Biosci. 2023 Jul 13;10:1225553. doi: 10.3389/fmolb.2023.1225553. eCollection 2023. Front Mol Biosci. 2023. PMID: 37520323 Free PMC article.
References
-
- Engvall E, Perlmann P. 1971. Enzyme-linked immunosorbent assay (ELISA). Quantitative assay of immunoglobulin G. Immunochemistry 8:871–874. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous